FORM 7

MONTHLY PROGRESS REPORT – July 2019

Name of Listed Issuer: **GREENSTAR BIOSCIENCES CORP.** (the "Issuer" or the “Company”).

Trading Symbol: **GSTR**

Number of Outstanding Listed Securities: **67,011,200**

Date: **August 5, 2019**

**Report on Business**

1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.

**Management has spent the month pursuing its business plan objectives. See the Issuer’s CSE Form 2A Listing Statement dated May 28, 2019 for a description of the Issuer’s business and business objectives. The Company plans to execute an aggressive growth plan over the short and medium term.**

1. Provide a general overview and discussion of the activities of management.

**In Washington State, the Issuer continues to lease assets and provide services to its tenant partner, Cowlitz County Cannabis Cultivation, Inc. (“Cowlitz”).**

1. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

**Not applicable.**

1. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

**Not applicable.**

1. Describe any new business relationships entered into between the Issuer, the Issuer’s affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

**Not applicable.**

1. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer’s affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

**On July 22, 2019, Ralph Olson resigned as President of the Company.**

**On July 22, 2019, Rene Usher resigned as a consultant of the Company. Ms. Usher was then appointed to the Strategic Advisory Board.**

**On July 22, 2019, Sean Campbell resigned as a Director of the Company. Mr. Campbell was then appointed to the Strategic Advisory Board.**

**On July 22, 2019, Scott Reeves resigned as a Corporate Secretary and Director of the Company. Mr. Reeves was then appointed to the Strategic Advisory Board.**

1. Describe any acquisitions by the Issuer or dispositions of the Issuer’s assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

**Not applicable.**

1. Describe the acquisition of new customers or loss of customers.

**Not applicable.**

1. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

**Not applicable.**

1. Report on any employee hiring’s, terminations or lay-offs with details of anticipated length of lay-offs.

**Not applicable.**

1. Report on any labour disputes and resolutions of those disputes if applicable.

**Not applicable.**

1. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

**Not applicable**

1. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

**Not applicable.**

1. Provide details of any securities issued and options or warrants granted.

**On July 22, 2019, the Company received resignations from option holders that included their voluntary cancellation of an aggregate of 1,525,008 options.**

**On July 29, 2019, the Company issued 200,000 stock options to a consultant of the Company. 100,000 options vested immediately with a further 100,000 options vesting on the anniversary of the grant July 29, 2020. Each option is exercisable into one common share of the Company at an exercise price of $0.20 per stock option until July 29, 2024.**

**On July 29, 2019, the Company issued 300,000 stock options to a consultant of the Company. All 300,000 options vest 60 days from the date of issue. Each option is exercisable into one common share of the Company at an exercise price of $0.20 per stock option until July 29, 2021.**

1. Provide details of any loans to or by Related Persons.

**Not applicable.**

1. Provide details of any changes in directors, officers or committee members.

**On July 25, 2019, the Company announced the appointment of Leighton Bocking to the Board of Directors. Mr. Bocking has over 15 years’ experience working in the capital markets and in corporate development roles. Mr. Bocking will fill one of the vacancies created as a result of the resignations of Scott Reeves, Ralph Olson and Sean Campbell from the Board. Rahim Rajwani, the Company’s Chief Executive Officer, will take on the role of Corporate Secretary from Mr. Reeves.**

1. Discuss any trends, which are likely to impact the Issuer including trends in the Issuer’s market(s) or political/regulatory trends.

**The Issuer’s flagship investments are in Washington State and currently management expects the legal and regulatory regimes in the United States (on a federal level), Washington State, and Canada to be the most relevant to its business.**

**United States**

**While the use of cannabis appears to be substantially increasing at the statelegalized level in the United States, the status of Federal legalization of cannabis in is uncertain. On February 14, 2019, William Barr was confirmed by the U.S. Senate as the next Attorney General. On January 15, 2019, during his confirmation hearing, Mr. Barr indicated that he personally believes cannabis should remain illegal but he also stated that if confirmed, he would not “go after companies that have relied on the 2013 Cole Memorandum and that his approach with regard to federal cannabis law enforcement would be “not to upset settled expectations.” Mr. Barr’s approach to cannabis federal law enforcement may prove less aggressive than Attorney General Session’s get-tough on cannabis stance and could reduce the uncertainty stemming from Attorney General Session’s tenure. However, Mr. Barr has made it clear that he does not support federal legalization and until he begins implementing these policies, considerable uncertainty remains. Jeff Sessions the former U.S. Attorney General was publicly opposed to the use of cannabis and on January 4, 2018, rescinded the Cole Memorandum, stating it was unnecessary. The Cole Memorandum was a document formerly issued by the Attorney General’s office (2013/2014) that gave guidance to prosecutors to focus their enforcement resources for marijuana offences on 8 priorities, including preventing distribution to minors, preventing revenue from going to organized crime and preventing impaired driving. It is likely that the States which have legalized marijuana for medical and/or recreational uses will fight any prohibition on the production, sale and use of cannabis, as they are receiving significant amounts of tax revenue in connection with these activities. The rescission of the Cole Memorandum introduced uncertainty to the market for the Company’s products. On December 20, 2018, the Agriculture Improvement Act of 2018 (the “2018 Farm Bill”) was passed into law. Marked as genuinely historic for the cannabis industry, the passing of the 2018 Farm Bill has removed all confusion associated with “industrial hemp”. While the Issuer has always utilized organically sourced US Dept. of Agriculture approved industrial hemp in its CBD products, “hemp”, defined as “the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis,” has now been officially removed from the Controlled Substances Act in the United States. While the Issuer is still assessing the various implications of the new law, the development is extremely positive for the Issuer and its future development plans in the U.S. and elsewhere. The safety of CBD and cannabis related products will remain of paramount importance for the Issuer and will continue to be a focus for consumers and regulators alike. Regulation of the industry is expected to increase, including new regulations anticipated from the US Food and Drug Administration (FDA). Despite these challenges and a general lack of access to banking, the cannabis industry has so far enjoyed access to capital markets. The situation is constantly evolving and there is a great degree of uncertainty over how matters will be settled, however, it is likely that these US states that have legalized cannabis will fight any prohibition on its use as they are receiving significant amounts of tax revenue from the sale of cannabis. Despite the legal, regulatory, and political obstacles the marijuana industry currently faces, the industry has continued to grow.**

**Washington State**

**On October 16, 2017, the Canadian Securities Administrators published Staff Notice 51-352 Issuers with U.S. Marijuana-Related Activities (“Staff Notice 51- 352”) which provides specific disclosure expectations for issuers that currently have, or are in the process of developing, cannabis-related activities in the United States as permitted within a particular state’s regulatory framework. All issuers with United States cannabis-related activities are expected to clearly and prominently disclose certain prescribed information in prospectus filings and other required disclosure documents. As a result of the Issuer’s investments in certain United States entities, the Issuer is subject to Staff Notice 51-352. See also the Issuer’s CSE Form 2A Listing Statement dated May 28, 2019.**

**Certificate of Compliance**

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated:August 5, 2019

Alex McAulay   
Name of Director or Senior Officer

(Signed) “Alex McAulay”   
Signature

Chief Financial Officer   
Official Capacity

|  |  |  |  |
| --- | --- | --- | --- |
| ***Issuer Details***  Name of Issuer  GreenStar Biosciences Corp. | For Month End  July 31, 2019 | | Date of Report  YY/MM/D  19/08/5 |
| Issuer Address  717-1030 West Georgia Street | | | |
| City/Province/Postal Code  Vancouver, BC V6E 2Y3 | | Issuer Fax No. | Issuer Telephone No.  604-834-9499 |
| Contact Name  Rahim Rajwani | | Contact Position CEO | Contact Telephone No.  604-628-2661 |
| Contact Email Address  Info@greenstarbiosciences.com | | Web Site Address  www.greenstarbiosciences.com | |